Bioasis Technologies Inc. (OTCMKTS:BIOAF) Short Interest Update
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Short Interest Update
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 42,600 shares, a growth of 23.1% from the July 31st total of 34,600 shares. Based on an average daily volume of 24,900 shares, the short-interest ratio is presently 1.7 days.
綠洲生物科技有限公司(場外交易代碼：BIOAF-GET Rating)是空頭股數8月份顯著增長的目標。截至8月15日，空頭股數共有4.26萬股，較7月31日的3.46萬股增長23.1%。以日均成交量24,900股計算，目前短息比率為1.7天。
Bioasis Technologies Price Performance
BiOASIS技術性價比
Shares of OTCMKTS BIOAF remained flat at $0.12 during mid-day trading on Friday. Bioasis Technologies has a 12 month low of $0.10 and a 12 month high of $0.28. The stock has a market capitalization of $9.53 million, a P/E ratio of -3.00 and a beta of 0.19. The company's 50 day simple moving average is $0.12 and its 200 day simple moving average is $0.16.
在週五午盤交易中，OTCMKTS BIOAF的股價持平於0.12美元。BiOasis Technologies的12個月低點為0.10美元，12個月高位為0.28美元。該股市值為953萬美元，市盈率為-3.00，貝塔係數為0.19。該公司的50日簡單移動均線切入位在0.12美元，200日簡單移動均線切入位在0.16美元。
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last posted its quarterly earnings data on Tuesday, June 14th. The company reported ($0.01) EPS for the quarter. As a group, equities research analysts forecast that Bioasis Technologies will post -0.05 EPS for the current fiscal year.
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)最近一次公佈季度收益數據是在6月14日(星期二)。該公司公佈了該季度每股收益(0.01美元)。作為一個整體，股票研究分析師預測，BiOasis Technologies本財年的每股收益將達到0.05歐元。
About Bioasis Technologies
關於BiOASIS技術公司
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技術公司是一家處於發展階段的生物製藥公司，致力於神經疾病和障礙的診斷和治療產品的研究和開發。它正在開發xB3，這是一種通過血腦屏障(BBB)運輸治療劑的平臺技術；以及治療中樞神經系統疾病(CNS)，包括腦癌，以及代謝和神經退行性疾病。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- 免費獲取StockNews.com關於BiOASIS技術的研究報告(BIOAF)
- 為什麼進軍高級汽車零部件可能是一個機會
- MarketBeat：回顧中的一週8/22-8/26
- 機構買入讓Marvell科技陷入低谷
- 戴爾股票因銷售疲軟而回落，跌入可怕的價值
- Dollar General的拉力賽有三個理由
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BiOasis Technologies及相關公司的評級的每日摘要。
譯文內容由第三人軟體翻譯。